Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs
Author:
Publisher
Elsevier BV
Subject
Radiology Nuclear Medicine and imaging,Oncology,General Medicine
Reference109 articles.
1. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma;Bukowski;Front Oncol,2012
2. NCCN guidelines updates: management of metastatic kidney cancer;Jonasch;J Natl Compr Canc Netw,2019
3. Tivozanib: first global approval;Kim;Drugs,2017
4. The role of tivozanib in advanced renal cell carcinoma therapy;Escudier;Expert Rev Anticancer Ther,2018
5. Tivozanib: status of development;Jamil;Curr Oncol Rep,2015
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. 4″-Alkyl EGCG Derivatives Induce Cytoprotective Autophagy Response by Inhibiting EGFR in Glioblastoma Cells;ACS Omega;2024-01-03
2. Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review;IJU Case Reports;2023-12-27
3. Emerging applications of anti-angiogenic nanomaterials in oncotherapy;Journal of Controlled Release;2023-12
4. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis;Journal of the Chinese Medical Association;2023-11-22
5. Multi-omics comprehensive analysis of renal clear cell carcinoma to distinguish subtypes with different molecular characterizations and therapeutic strategies;2023-07-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3